Publikationer COMBAT-MS

Publicerade artiklar om rituximab från projektets medlemmar

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al
JAMA Neurol 2020 Feb;77(2):184-191

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Spelman T, Frisell T, Piehl F, Hillert J. Mult Scler. 2018 Jul;24(8):1087-1095. doi: 10.1177/1352458517713668. PMID: 28649912

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al
Ann Neurol 2020 05;87(5):688-699

Rituximab, MS, and pregnancy. Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A.Neurol Neuroimmunol Neuroinflamm. 2020 May 1;7(4):e734. doi: 10.1212/NXI.0000000000000734. Print 2020 Jul. PMID: 32358226

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.
Granqvist M, Burman J, Gunnarsson M, Lycke J, Nilsson P, Olsson T, Sundström P, Svenningsson A, Vrethem M, Frisell T, Piehl F. Mult Scler. 2020 Oct;26(12):1532-1539. doi: 10.1177/1352458519866600. PMID: 31392923

Neurological manifestations of coronavirus infections - a systematic review.
Almqvist J, Granberg T, Tzortzakakis A, Klironomos S, Kollia E, Öhberg C, et al
Ann Clin Transl Neurol 2020 10;7(10):2057-2071

Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis.
Granberg T, Moridi T, Brand JS, Neumann S, Hlavica M, Piehl F, et al
J Neurol 2020 Jun;():

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab.
Razaz N, Piehl F, Frisell T, Langer-Gould AM, McKay KA, Fink K. Neurol Neuroimmunol Neuroinflamm. 2020 Oct 21;7(6):e903. doi: 10.1212/NXI.0000000000000903. Print 2020 Nov. PMID: 33087582

Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis.
Piehl F. J Intern Med. 2021 Jun;289(6):771-791. doi: 10.1111/joim.13215. PMID: 33258193

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis.
Alping P, Burman J, Lycke J, Frisell T, Piehl F. Neurology. 2021 Mar 16;96(11):e1574-e1584. doi: 10.1212/WNL.0000000000011545. PMID: 33514645

Risk of depression in multiple sclerosis across disease-modifying therapies.
Longinetti E, Frisell T, Englund S, Reutfors J, Fang F, Piehl F. Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128. PMID: 34264143

Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity.
Ineichen BV, Moridi T, Ewing E, Ouellette R, Manouchehrinia A, Stawiarz L, Ferreira D, Muehlboeck SJ, Kuhle J, Westman E, Leppert D, Hillert J, Olsson T, Kockum I, Piehl F, Granberg T. J Intern Med. 2021 Aug;290(2):473-476. doi: 10.1111/joim.13286. PMID: 33871105

Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis
Xu Y, Smith KA, Hiyoshi A, Piehl F, Olsson T, Montgomery S. Brain. 2021 Sep 4;144(8):2390-2400. doi: 10.1093/brain/awab100. PMID: 33693538

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies
Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, Sellebjerg F, Joensen H, Hillert J, Lycke J. JAMA Neurol. 2021 Oct 1;78(10):1197-1204. doi: 10.1001/jamaneurol.2021.2738. PMID: 34398221

Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis.
Ouellette R, Mangeat G, Polyak I, Warntjes M, Forslin Y, Bergendal Å, et al
Ann Neurol 2020 05;87(5):710-724

MRI-Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis.
Platten M, Martola J, Fink K, Ouellette R, Piehl F, Granberg T
J Neuroimaging 2020 03;30(2):198-204

Rituximab treatment for multiple sclerosis.
Ineichen BV, Moridi T, Granberg T, Piehl F
Mult Scler 2020 02;26(2):137-152

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.
Alping P, Piehl F, Langer-Gould A, Frisell T,
Epidemiology 2019 03;30(2):230-233

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.
Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, et al
Eur J Neurol 2019 08;26(8):1060-1067

 

Neuroimaging projects

7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis
Russell Ouellette, Constantina A. Treaba, Tobias Granberg, Elena Herranz, Valeria Barletta, Ambica Mehndiratta, Benjamin De Leene, Shahamat Tauhid, Fawad Yousuf, Sarah M. Dupont, Eric C. Klawiter, Jacob A. Sloane, Rohit Bakshi, Julien Cohen-Adad and Caterina Mainero. BRAIN 2020: 143; 2973–2987

Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosisz
Ouellette R, Mangeat G, Polyak I, Warntjes M, Forslin Y, Bergendal Å, Plattén M, Uppman M, Treaba CA, Cohen-Adad J, Piehl F, Kristoffersen Wiberg M, Fredrikson S, Mainero C, Granberg T. Ann Neurol. 2020 May;87(5):710-724. doi: 10.1002/ana.25705. PMID: 32057118

Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis
Michael Platten , Irene Brusini, Olle Andersson, Russell Ouellette , Fredrik Piehl, Chunliang Wang, Tobias Granberg. J Neuroimaging 2021;31:493-500. DOI: 10.1111/jon.12838

MRI-Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis
Michael Platten , Juha Martola, Katharina Fink, Russell Ouellette, Fredrik Piehl, Tobias GranbergJ Neuroimaging 2020;30:198-204. DOI: 10.1111/jon.12676

Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis
Michael Platten, Russell Ouellette, Elena Herranz, Valeria Barletta, Constantina A. Treaba, Caterina Mainero, Tobias Granberg. J Neuroimaging. 2022;1–9. DOI: 10.1111/jon.12977

Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis.
Irene Brusini, Michael Platten, Russell Ouellette, Fredrik Piehl, Chunliang Wang, Tobias Granberg. J Neuroimaging. 2022;1–12. DOI:10.1111/jon.12972

 

COVID enhancement projects:

Multiple sclerosis, rituximab, and COVID-19.
Annette Langer-Gould, Jessica B. Smith, Bonnie H. Li, the KPSC MS Specialist Group, Brandon E Beaber, Sonu M Brara, Julie Debacker, Allen Scott Nielsen, Samira Amirova & Oluwasheyi Ayeni. Annals of Clinical and Translational Neurology 2021; 8(4): 938–943

Rituximab infusion timing, cumulative dose, and hospitalization for COVID-19: Evidence from the nationwide COMBAT-MS Cohort
Kyla A McKay, Fredrik Piehl, Simon Englund, Anna He,Annette Langer-Gould, Jan Hillert, Thomas Frisell. JAMA accepted

Development of humoral and cellular immunological memory against SARS-CoV-2 despite B-cell depleting treatment in multiple sclerosis
Klara Asplund Högelin, Nicolas Ruffin, Elisa Pin, Anna Månberg, Sophia Hober, Guro Gafvelin, Hans Grönlund, Peter Nilsson, Mohsen Khademi, Tomas Olsson, Fredrik Piehl, Faiez Al Nimer. ISCIENCE (2021)

False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases.
Kharlamova N, Dunn N, Bedri SK, Jerling S, Almgren M, Faustini F, Gunnarsson I, Rönnelid J, Pullerits R, Gjertsson I, Lundberg K, Månberg A, Pin E, Nilsson P, Hober S, Fink K, Fogdell-Hahn A. Front Immunol. 2021 May 3;12:666114. doi: 10.3389/fimmu.2021.666114. eCollection 2021. PMID: 34012450

Intratekal behandling med rituximab i progressiv MS - en fas 1b studie:

Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.
Bergman J, Burman J, Gilthorpe JD, Zetterberg H, Jiltsova E, Bergenheim T, et al
Neurology 2018 11;91(20):e1893-e1901

Studien visade att 1 av 7 hade behandlingseffekt efter ett år, ingen hade någon skillnad i 6 CSF biomarkörer och en hade bakteriell meningit (som behandlades effektivt).

B-celler roll i MS:

Faiez Al Nimer och hans post-doc grupp i Zürich har i samarbete med KI gruppen publicerat en artikel i Cell om minnes-B-celler och dess roll vid MS:

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.
Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, et al
Cell 2018 09;175(1):85-100.e23

(I korthet beskrivs autoproliferation av CD4 T-celler i MS, speciellt hos DRB1*15:01 positiva, som drivs av minnes B-cells och som ”stängs av” med rituximab behandling, när minnes B-cellerna elimineras. Efter 3-4 doser rituximab kan man räkna med att minnes B cell poolen i stort är eliminerad och frågan är då hur långvarig effekten är. Observationer både i Umeå och Stockholm indikerar att risken för att få ny sjukdomsaktivitet över 2-3 år är mycket låg, vilket ju liknar andra induktionsbehandlingar som alemtuzumab och kladribin. Detta har potentiellt stor klinisk betydelse t ex vid infektionskänslighet och påfyllnad av vaccination. Eftersom vi vet att man får sämre vaccinationssvar under behandling skulle man kunna våga låta B-celler återkomma mer och passa på att förbättra vaccinationsskyddet under en period.)

Kombination av MRI och biomarkörer i CSF för att predicera sekundär progressiv sjukdom:

Joachim har tillsammans med kollegor i Uppsala publicerat följande artikel:

Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis.
Herman S, Khoonsari PE, Tolf A, Steinmetz J, Zetterberg H, Åkerfeldt T, et al
Theranostics 2018 ;8(16):4477-4490

I korthet har man med hjälp av metabolit- och proteinanalyser av CSF kunna identifiera SPMS på tidigt stadium. Med 11 olika variabler kunde man skilja på RRMS och SPMS och med fyra ytterligare markörer även progression.

Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, et al
Mult. Scler. 2018 08;24(9):1224-1233

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al
JAMA Neurol 2018 03;75(3):320-327

Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS.
de Flon P, Laurell K, Söderström L, Gunnarsson M, Svenningsson A
Mult. Scler. 2017 Aug;23(9):1249-1257

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, et al
Neurology 2016 Nov;87(20):2074-2081

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T, et al
Neurology 2016 Jul;87(2):141-7

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, et al
Ann. Neurol. 2016 Jun;79(6):950-8

Rituximab in paediatric onset multiple sclerosis: a case series.
Salzer J, Lycke J, Wickström R, Naver H, Piehl F, Svenningsson A
J. Neurol. 2016 Feb;263(2):322-326